Literature DB >> 11522620

Loss of annexin II heavy and light chains in prostate cancer and its precursors.

A Chetcuti1, S H Margan, P Russell, S Mann, D S Millar, S J Clark, J Rogers, D J Handelsman, Q Dong.   

Abstract

Annexin II mRNA coding for a calcium binding protein was found to be absent in prostate cancer by subtractive hybridization and Northern analysis. In contrast to high expression in normal and benign hyperplastic glandular and basal epithelium, Annexin II heavy (p36) and light (p11) chains in 31/31 prostate cancer specimens were lost immunohistochemically. In glands involved by prostate intraepithelial neoplasia, 65% lost both chains in glandular epithelial cells, whereas basal cells were all positively stained. Southern analysis of cancer DNA showed no noticeable deletion in p36 gene. LNCaP cells treated with 5-azacytidine re-expressed p36, suggesting methylation could be responsible for the silencing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522620

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Identification of differentially expressed proteins between human esophageal immortalized and carcinomatous cell lines by two-dimensional electrophoresis and MALDI-TOF-mass spectrometry.

Authors:  Xing-Dong Xiong; Li-Yan Xu; Zhong-Ying Shen; Wei-Jia Cai; Jian-Min Luo; Ya-Li Han; En-Min Li
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

Review 2.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

3.  Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms.

Authors:  Mario Menschikowski; Albert Hagelgans; Eugene Gussakovsky; Heike Kostka; Elena L Paley; Gabriele Siegert
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

4.  Annexin II binds to SHP2 and this interaction is regulated by HSP70 levels.

Authors:  Jae Cheal Yoo; Michael J Hayman
Journal:  Biochem Biophys Res Commun       Date:  2007-03-19       Impact factor: 3.575

5.  Proteome analysis of the transformation potential of the Epstein-Barr virus-encoded latent membrane protein 1 in nasopharyngeal epithelial cells NP69.

Authors:  Qiong Zhang; Zhiwei Zhang; Chengkun Wang; Zhiqiang Xiao; Yanhui Yu; Fang Yang; Zhuchu Chen; Zhimin He
Journal:  Mol Cell Biochem       Date:  2008-04-19       Impact factor: 3.396

6.  Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.

Authors:  Jocelyn Stewart; Neil Fleshner; Heather Cole; Joan Sweet
Journal:  J Clin Pathol       Date:  2006-08-17       Impact factor: 3.411

7.  ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.

Authors:  Nicholas B Griner; Denise Young; Pankaj Chaudhary; Ahmed A Mohamed; Wei Huang; Yongmei Chen; Taduru Sreenath; Albert Dobi; Gyorgy Petrovics; Jamboor K Vishwanatha; Isabell A Sesterhenn; Shiv Srivastava; Shyh-Han Tan
Journal:  Mol Cancer Res       Date:  2014-10-24       Impact factor: 5.852

8.  Isolation and preliminary characterization of herpes simplex virus 1 primary enveloped virions from the perinuclear space.

Authors:  Maryn E Padula; Mariam L Sydnor; Duncan W Wilson
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

9.  Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer.

Authors:  Manish I Patel; Jaskirat Singh; Marzieh Niknami; Caroline Kurek; Mu Yao; Sasa Lu; Fiona Maclean; Nicholas J C King; Michael H Gelb; Kieran F Scott; Pamela J Russell; John Boulas; Qihan Dong
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

10.  Annexin II represents metastatic potential in clear-cell renal cell carcinoma.

Authors:  Y Ohno; M Izumi; T Kawamura; T Nishimura; K Mukai; M Tachibana
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.